Skip to main content

Advertisement

Log in

Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Control—In Search of the Optimal Treatment

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The optimal management of patients with clinically localized prostate carcinoma remains undefined due in part to the absence of well-designed, randomized trials.

Methods

This retrospective study comprised 505 patients diagnosed with low- or intermediate- risk prostate cancer in 1998–2005 and treated at Hospital Gregorio Marañón (Spain) with radical prostatectomy (RP) or external-beam radiotherapy (EBRT). No adjuvant therapy was administered. Biochemical relapse was defined as a prostate-specific antigen (PSA) level ≥0.4 ng/ml for RP cases and nadir + 2 for EBRT cases. RP was performed in 271 patients (53.6%) and EBRT in 234 patients (46.4%). The median follow-up was 60 months. The analysis end point was to compare the biochemical recurrence-free survival (bRFS) between the two groups.

Results

The 5-year bRFS rates for RP and EBRT were 79 ± 2% and 86 ± 2%, respectively (P = 0.48). Multivariate analysis indicated that initial PSA (P = 0.00), perineural invasion in the biopsy specimen (P = 0.00), Gleason score (P = 0.04), EBRT dose (P = 0.02), and positive margins (P = 0.00) were independent predictors of relapse. A decision tree model was constructed with these variables. In the EBRT cohort, a nadir PSA of <0.3 ng/ml was associated with the best 5-year bRFS (96.6 vs. 56.5% if nadir PSA > 1.3 ng/ml). Late biochemical failure (>5 years) was more frequent in the RT group and with low-dose EBRT (≤72 Gy).

Conclusions

The biochemical failure rates were similar between PR and EBRT in low- and intermediate-risk subgroups. Outcome was determined by classic pre-treatment features, perineural invasion, low-dose EBRT (≤72 Gy), and nadir PSA value in the RT cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376–85.

    Article  PubMed  Google Scholar 

  2. Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95:2126–35.

    Article  PubMed  Google Scholar 

  3. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–6.

    Article  PubMed  Google Scholar 

  4. Thompson I, Thrasher JB, Aus G, et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31.

    Article  PubMed  Google Scholar 

  5. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. v.2.2009. Available at: http://www.nccn.org/.

  6. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. 2009. Available at: http://www.uroweb.org/professional-resources/guidelines/.

  7. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045–53.

    Article  PubMed  Google Scholar 

  8. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2003;4:233–41.

    Article  PubMed  Google Scholar 

  9. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.

    Article  PubMed  Google Scholar 

  10. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973–8.

    Article  PubMed  CAS  Google Scholar 

  11. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.

    Article  PubMed  Google Scholar 

  12. Paulson DF, Lin GH, Hinshaw W. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128:502–5.

    PubMed  CAS  Google Scholar 

  13. Vassil AD, Murphy ES, Reddy CA, et al. Five-year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology. 2010;76:1251–7.

    Article  PubMed  Google Scholar 

  14. Parker CC, Dearnaley DP. Radical radiotherapy for prostate cancer. Cancer Treat Rev. 2003;29:161–9.

    Article  PubMed  CAS  Google Scholar 

  15. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129–36.

    Article  PubMed  CAS  Google Scholar 

  16. Arcangeli G, Strigari L, Argandeli S, et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75:975–82.

    Article  PubMed  Google Scholar 

  17. Blood PA, Pickles T. The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer. Radiat Oncol. 2007;2:17–21.

    Article  PubMed  Google Scholar 

  18. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatec-tomy. J Urol. 2001;165:119–25.

    Article  PubMed  CAS  Google Scholar 

  19. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33.

    Article  PubMed  Google Scholar 

  20. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–105.

    Article  PubMed  Google Scholar 

  21. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol. 2007;84:197–215.

    Article  PubMed  Google Scholar 

  22. Zietman AL, Bae K, Slater JD, et al. Adenocarcinoma of the prostate: long-term results from proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106–11.

    Article  PubMed  Google Scholar 

  23. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–13.

    Article  PubMed  Google Scholar 

  24. Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies. A systematic review. Cancer. 2007;109:13–24.

    Article  PubMed  Google Scholar 

  25. Yu HHM, Song DY, Tsai YY, Thompson T, Frassica DA, DeWeese TL. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology. 2007;70:111–6.

    Article  PubMed  Google Scholar 

  26. Ozcan F. Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. Eur Urol. 2001;40:308–12.

    Article  PubMed  CAS  Google Scholar 

  27. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–8.

    Article  PubMed  Google Scholar 

  28. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol. 2009;181:956–62.

    Article  PubMed  Google Scholar 

  29. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.

    Article  PubMed  Google Scholar 

  30. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D’Amico A. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008;71:136–40.

    Article  PubMed  Google Scholar 

  31. Ray ME, Levy LB, Horwitz EM, et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006;68:1257–62.

    Article  PubMed  Google Scholar 

  32. Malcolm JB, Fabrizio MD, Barone BB, et al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol. 2010;183:1822–9.

    Article  PubMed  Google Scholar 

  33. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We are grateful to Thomas O’Boyle for editorial assistance.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carmen González-San Segundo MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

González-San Segundo, C., Herranz-Amo, F., Álvarez-González, A. et al. Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Control—In Search of the Optimal Treatment. Ann Surg Oncol 18, 2980–2987 (2011). https://doi.org/10.1245/s10434-011-1660-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1660-0

Keywords

Navigation